Home > Healthcare > Pharmaceuticals > Finished Drug Form > Cephalosporin Drugs Market

Cephalosporin Drugs Market Trends

Report ID: GMI8194
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Cephalosporin Drugs Market Trends

The cephalosporin drugs industry has experienced a significant boost in recent years, largely attributed to the increasing trend of partnerships and collaborations among market players.
Recognizing the escalating global threat of antimicrobial resistance, pharmaceutical companies, research institutions, and governmental organizations are actively engaging in strategic alliances to pool resources, share expertise, and expedite the development and commercialization of novel cephalosporin drugs.
For instance, in June 2022, Shionogi & Co., Ltd. and the Global Antibiotic Research and Development Partnership (GARDP) entered into a collaborative agreement with the Clinton Health Access Initiative (CHAI) to expand access to cefiderocol antibiotic for the treatment of serious gram-negative bacterial infections.
Thus, such growing collaborations among market players play a pivotal in accelerating innovation and advancing the development of new generation drugs, thereby fostering the growth of market.

However, increasing antibiotic resistance is a significant pitfall for the cephalosporin drugs industry. Cephalosporin-resistant strains of bacteria can emerge, rendering cephalosporins less effective in treating infections caused by these resistant organisms.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global cephalosporin drugs industry was valued at USD 14.1 billion in 2023 and is estimated to grow at a CAGR of 3.1% between 2024 and 2032, attributed to growing number of generic medications, rising geriatric population, and advancements in drug discovery services.

The parenteral segment is expected to reach a notable market revenue of USD 11.3 billion by 2032, owing to the rapid and direct delivery of the drug into the bloodstream.

In 2023, North America held a significant share of 42.2% in the cephalosporin drugs market, backed by substantial investments in pharmaceuticals, including the purchase and use of cephalosporin drugs.

AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.